Chardan Capital Keeps Buy on SAB Biotherapeutics, Raises PT to $14

miércoles, 11 de marzo de 2026, 2:46 pm ET1 min de lectura
SABS--

Chardan Capital Keeps Buy on SAB Biotherapeutics, Raises PT to $14

Chardan Capital Keeps Buy on SAB Biotherapeutics, Raises PT to $14

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios